Conference Reports for NATAP

Back

Digestive Disease Week 2007 Washington DC May 19-24, 2007     Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (06/05/07)   12 weeks VX-950 Therapy - (06/04/07)   Patient survey, Many hepatitis B patients stop taking meds - (05/31/07)   NY Montefiore Hospital Coinfection Program Reports Success With a Multi-Disciplinary Program: Model of Care - (05/31/07)   Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD): does fatty liver cause lipodystrophy? - (05/25/07)   Diabetes Therapy Improves Peg/RBV Response - (05/25/07)   Early Pegasys/RBV Therapy is Cost Effective, Improves Survival & Reduces Risk for Cirrhosis - (05/25/07)   Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration - (05/25/07)   A Randomized Trial of Telbivudine vs Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine - (05/25/07)   A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients With Chronic Hepatitis B: Two-Year Results - (05/25/07)   Causes of Death Associated With Hepatitis B or Hepatitis C Virus Infections in a Long-Term Population-Based Cohort Study - (05/24/07)   Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD) - (05/24/07)   Cost-effectiveness, Survival, and Prevention of Cirrhosis with Early Treatment of Chronic Hepatitis C with Peginterferon Alfa-2a (40KD) plus Ribavirin before Progression to Advanced Liver Disease - (05/24/07)   HCV Can Be Cured - (05/24/07)   Treatment Duration and Histological Response to Peginterferon Alfa-2a/Ribavirin: 48 weeks improves liver disease in Non-SVRs better than 24 weeks - (05/24/07)   Salvage Therapy With Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients From the GLOBE Study - (05/23/07)   Safety and Tolerability of Peginterferon Alfa-2a Plus Ribavirin in HCV Patients Nontolerant or Nonresponsive to Peginterferon Alfa-2b Plus Ribavirin - (05/23/07)   Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C - (05/23/07)   Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Pegylated Interferon Alfa-2b in Treatment-Naive Patients With Chronic HCV - (05/23/07)   Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common Even When ALT is Less Than 2 x ULN in Patients with Chronic Hepatitis B (CHB) in Entecavir Studies ETV-022 (HBeAg+) and ETV-027 (HBeAg-) - (05/23/07)   Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial - (05/23/07)   Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial - (05/23/07)   BARACLUDE (ENTECAVIR) TREATMENT DEMONSTRATED GREATER VIRAL LOAD REDUCTION COMPARED TO ADEFOVIR AT 48 WEEKS IN STUDY OF ANTIVIRAL-NAIVE CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (05/23/07)   HCV-Infected Liver Donors for Liver Transplantation Are Recommended Instead of Uninfected HCV-Donated Livers, from a new study presented at DDW 2007 - (05/22/07)   HCV-796, Polymerase Inhibitor - (05/22/07)   Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (05/22/07)   Increased SVR rate with 48 weeks' treatment and higher RBV dose in HCV genotype 2/3 patients without a rapid virologic response (RVR) treated with peginterferon alfa-2a (40KD) (PEGASYS) plus RBV (COPEGUS) - (05/22/07)   Peginterferon Alfa-2a (40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis - (05/22/07)   Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''; Mitch Shiffman says 'you can cure HCV', Eugene Schiff says 'get treated'. - (05/22/07)   16 vs 24 wks Pegasys/RBV in Cirrhotics & Non-Cirrhotics Genotype 2/3 from ACCELERATE Study - (05/22/07)   InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting - (05/21/07)   Telbivudine GLOBE Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B - (05/21/07)   HBV DNA & Genotype Predict HCC - (05/21/07)   HBV DNA & ALT Predict HCC in HBV+ - (05/21/07)   Statin Improved PegIFN/RBV SVR Rate, Improve ALTs in HCV+ - (05/21/07)   Increased SVR Rate with 48 Wks' Treatment and Higher RBV Dose in HCV Genotype 2/3 Pts Without a Rapid Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS) Plus RBV (COPEGUS) - (05/21/07)